pubmed-article:12100148 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:12100148 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:12100148 | lifeskim:mentions | umls-concept:C1457887 | lld:lifeskim |
pubmed-article:12100148 | lifeskim:mentions | umls-concept:C0085133 | lld:lifeskim |
pubmed-article:12100148 | lifeskim:mentions | umls-concept:C0021760 | lld:lifeskim |
pubmed-article:12100148 | lifeskim:mentions | umls-concept:C0019829 | lld:lifeskim |
pubmed-article:12100148 | lifeskim:mentions | umls-concept:C0677874 | lld:lifeskim |
pubmed-article:12100148 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
pubmed-article:12100148 | lifeskim:mentions | umls-concept:C0231174 | lld:lifeskim |
pubmed-article:12100148 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
pubmed-article:12100148 | lifeskim:mentions | umls-concept:C0150312 | lld:lifeskim |
pubmed-article:12100148 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
pubmed-article:12100148 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
pubmed-article:12100148 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
pubmed-article:12100148 | pubmed:issue | 1 | lld:pubmed |
pubmed-article:12100148 | pubmed:dateCreated | 2002-7-8 | lld:pubmed |
pubmed-article:12100148 | pubmed:abstractText | Interleukin 6 (IL-6) is a potent immunomodulatory cytokine that has pathogenic and prognostic significance in a number of disorders. Previous studies in Hodgkin's disease (HD) have demonstrated the association between elevated serum levels of IL-6 and unfavourable prognosis, including advanced stage and the presence of 'B' symptoms and with reduced survival. Although IL-6 expression has been demonstrated in both the malignant Hodgkin/Reed-Sternberg (HRS) cells and in the various non-malignant cells present in HD biopsies, a relationship between expression of IL-6 by the tumour and outcome measures has not been established. The study group comprised of 97 patients with advanced HD who were recruited to two related clinical trials. IL-6 expression was determined on paraffin-wax sections of biopsy material by means of an immunohistochemical assay. Of the 97 patients, 27 (28%) showed staining for IL-6 in HRS cells. IL-6 expression by HRS cells was significantly correlated with a decreased likelihood of achieving a complete response to chemotherapy (P = 0.02) and with an increased prevalence of 'B' symptoms (P = 0.04). IL-6 expression by HRS cells was not associated with Epstein-Barr virus status (P = 0.57). In summary, the results suggest that IL-6 expression by HRS cells may contribute to the presence of 'B' symptoms and to a decreased likelihood to achieve a complete remission in HD patients. | lld:pubmed |
pubmed-article:12100148 | pubmed:language | eng | lld:pubmed |
pubmed-article:12100148 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12100148 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:12100148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12100148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12100148 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:12100148 | pubmed:month | Jul | lld:pubmed |
pubmed-article:12100148 | pubmed:issn | 0007-1048 | lld:pubmed |
pubmed-article:12100148 | pubmed:author | pubmed-author:NelsonPaulP | lld:pubmed |
pubmed-article:12100148 | pubmed:author | pubmed-author:YoungLawrence... | lld:pubmed |
pubmed-article:12100148 | pubmed:author | pubmed-author:CrockerJohnJ | lld:pubmed |
pubmed-article:12100148 | pubmed:author | pubmed-author:NajafipourSoh... | lld:pubmed |
pubmed-article:12100148 | pubmed:author | pubmed-author:ReynoldsGary... | lld:pubmed |
pubmed-article:12100148 | pubmed:author | pubmed-author:BillinghamLuc... | lld:pubmed |
pubmed-article:12100148 | pubmed:author | pubmed-author:GrayLaura JLJ | lld:pubmed |
pubmed-article:12100148 | pubmed:author | pubmed-author:FlavellJoanne... | lld:pubmed |
pubmed-article:12100148 | pubmed:author | pubmed-author:MurrayPaul... | lld:pubmed |
pubmed-article:12100148 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:12100148 | pubmed:volume | 118 | lld:pubmed |
pubmed-article:12100148 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:12100148 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:12100148 | pubmed:pagination | 195-201 | lld:pubmed |
pubmed-article:12100148 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
pubmed-article:12100148 | pubmed:meshHeading | pubmed-meshheading:12100148... | lld:pubmed |
pubmed-article:12100148 | pubmed:meshHeading | pubmed-meshheading:12100148... | lld:pubmed |
pubmed-article:12100148 | pubmed:meshHeading | pubmed-meshheading:12100148... | lld:pubmed |
pubmed-article:12100148 | pubmed:meshHeading | pubmed-meshheading:12100148... | lld:pubmed |
pubmed-article:12100148 | pubmed:meshHeading | pubmed-meshheading:12100148... | lld:pubmed |
pubmed-article:12100148 | pubmed:meshHeading | pubmed-meshheading:12100148... | lld:pubmed |
pubmed-article:12100148 | pubmed:meshHeading | pubmed-meshheading:12100148... | lld:pubmed |
pubmed-article:12100148 | pubmed:meshHeading | pubmed-meshheading:12100148... | lld:pubmed |
pubmed-article:12100148 | pubmed:meshHeading | pubmed-meshheading:12100148... | lld:pubmed |
pubmed-article:12100148 | pubmed:meshHeading | pubmed-meshheading:12100148... | lld:pubmed |
pubmed-article:12100148 | pubmed:meshHeading | pubmed-meshheading:12100148... | lld:pubmed |
pubmed-article:12100148 | pubmed:meshHeading | pubmed-meshheading:12100148... | lld:pubmed |
pubmed-article:12100148 | pubmed:meshHeading | pubmed-meshheading:12100148... | lld:pubmed |
pubmed-article:12100148 | pubmed:meshHeading | pubmed-meshheading:12100148... | lld:pubmed |
pubmed-article:12100148 | pubmed:meshHeading | pubmed-meshheading:12100148... | lld:pubmed |
pubmed-article:12100148 | pubmed:meshHeading | pubmed-meshheading:12100148... | lld:pubmed |
pubmed-article:12100148 | pubmed:year | 2002 | lld:pubmed |
pubmed-article:12100148 | pubmed:articleTitle | Interleukin 6 expression by Hodgkin/Reed-Sternberg cells is associated with the presence of 'B' symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease. | lld:pubmed |
pubmed-article:12100148 | pubmed:affiliation | The Liver Research Laboratories, CRC Institute for Cancer Studies, Department of Pathology, University of Birmingham, Edgbaston, UK. | lld:pubmed |
pubmed-article:12100148 | pubmed:publicationType | Journal Article | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12100148 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12100148 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12100148 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12100148 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12100148 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12100148 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12100148 | lld:pubmed |